U of Alberta Researchers Win $120K Grant to Develop Metabolite-Based Lung Cancer Test

u of alberta researchers win 120 grant to develop metabolite based lung cancer test

Mar 16, 2021 | staff reporter

NEW YORK — BioMark Diagnostics said on Tuesday that its collaborators at the University of Alberta’s Metabolomics Innovation Centre have been awarded a C$150,000 (US$120,327) grant to evaluate the company’s metabolite biomarker panel for early lung cancer detection.

The funding is being provided through a cancer technology grant program sponsored by the Canadian Cancer Society, the Canadian Institutes of Health Research — Institute of Cancer Research, and the Brain Canada Foundation.

According to BioMark, the Metabolomics Innovation Centre will use the grant to validate the biomarker panel in over 1,200 patients. At the end of the award period, the Vancouver-based company said it expects have a laboratory-developed test that can be used on commonly used mass spectrometry platforms and a plan to launch the test, first through an accredited lab in Quebec and later Canada-wide.

Since BioMark and the Metabolomics Innovation Centre began working together in early 2015, “we have worked hard to establish metabolite biomarkers that are specific to lung cancer in plasma samples and now we begin the final stretch in validating our test toward commercialization across Canada,” BioMark President and CEO Rashid Ahmed Bux said in a statement.

Source: https://www.360dx.com/cancer/u-alberta-researchers-win-120k-grant-develop-metabolite-based-lung-cancer-test#.YFDqIJ1KiUk

 

Share this post:
Categories
Archives

Sign up for the latest Biomark news

No paperwork, no hassle. We keep things digital, easy and regular.

*Zero Spam Policy. You will need to confirm your email address to receive our news to your inbox.

BioMark Diagnostics Inc.
CSE: BUX
OTC: BMKDF
FSE: 20B
Investors

Related articles ...

© 2021 BioMark Diagnostics Inc. All Rights Reserved. BioMark’s mission is to provide universal access to a new paradigm in cancer diagnostics using metabolomics.